secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-020847
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics Q1 net loss $44.2M; on track for initial trial data H2 2023
-----------------------------------------------------------------------------

- Net loss $44.2M ($0.78/share) vs $35.6M ($0.69) in Q1 2022.
- Cash $238.2M at March 31; raised $24.2M via ATM after quarter; funds through 2024.
- R&D expenses $37.5M, up from $28.2M YoY.
- Enrollment continues in ACHIEVE (DM1) and DELIVER (DMD) trials; initial data expected H2 2023.
- DYNE-251 granted orphan drug and rare pediatric disease designations by FDA in March 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000095017023020847/0000950170-23-020847-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000095017023020847/dyn-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020847

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer